Mucositis after allogeneic hematopoietic stem cell transplantation: A cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens

Biology of Blood and Marrow Transplantation

Volumn 11, Issue 5, 2005, Pages 383-388

  Cutler, Corey ^a   Li, Shuli ^a   Kim, Haesook T ^a   Laglenne, Patricia ^b   Szeto, Kwok Chuen ^b   Hoffmeister, Laura ^b   Harrison, M Joel ^b   Ho, Vincent ^a   Alyea, Edwin ^a   Lee, Stephanie J ^a   Soiffer, Robert ^a   Sonis, Stephen ^b   Antin, Joseph H ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Oral mucositis; Sirolimus; Stem cell transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE; RAPAMYCIN; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRANULOCYTIC LEUKEMIA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HOSPITAL DISCHARGE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PROSPECTIVE STUDY; QUALITY OF LIFE; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TOTAL PARENTERAL NUTRITION; WHOLE BODY RADIATION;

ADULT; COHORT STUDIES; DRUG EVALUATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENGTH OF STAY; MALE; METHOTREXATE; MIDDLE AGED; MOUTH MUCOSA; PREMEDICATION; RETROSPECTIVE STUDIES; SIROLIMUS; STOMATITIS; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 20244362642     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.02.006     Document Type: Article

References (32)

1. S.T. Sonis The pathobiology of mucositis Nat Rev Cancer 4 2004 277-284
2. S.B. Woo S.T. Sonis M.M. Monopoli A.L. Sonis A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients Cancer 72 1993 1612-1617
3. L.A. Bellm J.B. Epstein A. Rose-Ped P. Martin H.J. Fuchs Patient reports of complications of bone marrow transplantation Support Care Cancer 8 2000 33-39
4. P. Stiff Mucositis associated with stem cell transplantation: Current status and innovative approaches to management Bone Marrow Transplant. 27 suppl 2 2001 S3-S11
5. S.T. Sonis G. Oster H. Fuchs et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation J Clin Oncol. 19 2001 2201-2205
6. J. Filicko H.M. Lazarus N. Flomenberg Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: New approaches to prophylaxis and treatment Bone Marrow Transplant. 31 2003 1-10
7. E.B. Rubenstein D.E. Peterson M. Schubert et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis Cancer 100 9 suppl 2004 2026-2046
8. K. Robien M.M. Schubert B. Bruemmer M.E. Lloid J.D. Potter C.M. Ulrich Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia J Clin Oncol. 22 2004 1268-1275
9. J.H. Antin H.T. Kim C. Cutler et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation Blood 102 2003 1601-1605
10. C. Cutler H.T. Kim E.P. Hochberg et al. Sirolimus and tacrolimus without methotrexate as graft-vs.-host disease prophylaxis after matched, related donor peripheral blood stem cell transplantation Biol Blood Marrow Transplant. 10 2004 328-336
11. S.T. Sonis J.P. Eilers J.B. Epstein et al. Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group Cancer 85 1999 2103-2113
12. American Pain Society Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain 5th ed. 2003 American Pain Society Glenview, IL
13. B. Bolwell R. Sobecks B. Pohlman et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation Bone Marrow Transplant. 34 2004 621-625
14. B. Borowski E. Benhamou J.L. Pico A. Laplanche J.P. Margainaud M. Hayat Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: A randomised controlled trial comparing two protocols of dental care Eur J Cancer B Oral Oncol. 30B 1994 93-97
15. P.M. Anderson N.K. Ramsay X.O. Shu et al. Effect of low-dose oral glutamine on painful stomatitis during bone marrow transplantation Bone Marrow Transplant. 22 1998 339-344
16. P.R. Schloerb B.S. Skikne Oral and parenteral glutamine in bone marrow transplantation: A randomized, double-blind study JPEN J Parenter Enteral Nutr. 23 1999 117-122
17. K. Atkinson J.C. Biggs K. Downs et al. GM-CSF after allogeneic bone marrow transplantation: Accelerated recovery of neutrophils, monocytes and lymphocytes Aust N Z J Med. 21 1991 686-692
18. J. Nemunaitis C.S. Rosenfeld R. Ash et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation Bone Marrow Transplant. 15 1995 949-954
19. D. Valcarcel M.A. Sanz Jr A. Sureda et al. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study Bone Marrow Transplant. 29 2002 783-787
20. C. Dazzi A. Cariello P. Giovanis et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: A double blind, randomized, placebo-controlled study Ann Oncol. 14 2003 559-563
21. J.H. Antin S.J. Lee D. Neuberg et al. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation Bone Marrow Transplant. 29 2002 373-377
22. J. Schwerkoske L. Schwartzberg C. Weaver U. Schwertschlag J. Goodfellow C. Bedrosian A phase I, double-masked, placebo-controlled study to evaluate tolerability of Neumega (rh IL-11; opreleukin) to reduce mucositis in patients with solid tumors or lymphoma receiving high dose chemotherapy with autologous peripheral blood stem cell reinfusion [abstract] Proc Am Soc Clin Oncol. 18 1999 584a
23. J.P. Donnelly L.A. Bellm J.B. Epstein S.T. Sonis R.P. Symonds Antimicrobial therapy to prevent or treat oral mucositis Lancet Infect Dis. 3 2003 405-412
24. F.J. Giles C.B. Miller D.D. Hurd et al. A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial) Leuk Lymphoma. 44 2003 1165-1172
25. E. Alvarez E.G. Fey P. Valax et al. Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/ radiation-induced oral mucositis Clin Cancer Res. 9 2003 3454-3461
26. R. Spielberger P. Stiff W. Bensinger et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers N Engl J Med. 351 2004 2590-2598
27. P. Stiff W. Bensinger C. Emmanouilides et al. Treatment of mucositis with palifermin improves patient function and results in a clinically meaningful reduction in mouth and throat soreness (MTS) phase 3 results [abstract] Blood 102 2003 676a
28. C. Emmanouilides R. Spielberger P. Stiff et al. Palifermin treatment of mucositis in transplant patients reduces health resource use: Phase 3 results [abstract] Blood 102 2004 883a
29. S.J. Lee D. Zahrieh E.P. Alyea et al. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: Clinical outcomes, quality of life, and costs Blood 100 2002 2697-2702
30. M.J. Dodd S. Dibble C. Miaskowski et al. A comparison of the affective state and quality of life of chemotherapy patients who do and do not develop chemotherapy-induced oral mucositis J Pain Symptom Manage. 21 2001 498-505
31. J.B. Epstein N. Phillips J. Parry M.S. Epstein T. Nevill P. Stevenson-Moore Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation Bone Marrow Transplant. 30 2002 785-792
32. L.A. Bellm G. Cunningham L. Durnell et al. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis oral mucositis: Patient provider advisory board Cancer Invest. 20 2002 793-800